GlassScriptPhysician profile
James W Rogers
NPI 1942208434
$636.45
in general payments reported to CMS, 2019-2025
20 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.32 · 2021: $25.87 · 2023: $19.22 · 2024: $107 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $82.61 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.97 | 2025 | Caplyta |
| Lundbeck LLC | $60.25 | 2024-2025 | Rexulti |
| Pfizer INC. | $50.68 | 2019-2025 | |
| Dexcom, INC. | $46.00 | 2024-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $40.88 | 2025 | Zenpep |
| Abbvie INC. | $38.73 | 2025 | |
| Exact Sciences Corporation | $29.23 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $27.34 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $26.00 | 2024 | Voquezna |
| Eisai INC. | $25.87 | 2021 | |
| Abbott Laboratories | $19.22 | 2023 | Proclaim |
| Lilly USA, LLC | $17.40 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2025 | Jardiance |
| Viatris Specialty LLC | $16.22 | 2025 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.72 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $14.64 | 2024 | |
| Merck Sharp & Dohme LLC | $14.49 | 2025 | Vaxelis, Capvaxive, Gardasil 9 |
| Tactile Systems Technology INC | $11.37 | 2019 | |
| Organon LLC | $9.97 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.